Leo Wealth LLC Sells 16,394 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Leo Wealth LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,705 shares of the biopharmaceutical company's stock after selling 16,394 shares during the quarter. Leo Wealth LLC's holdings in Gilead Sciences were worth $1,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp raised its stake in Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after buying an additional 841,776 shares during the last quarter. Wellington Management Group LLP grew its holdings in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the period. FMR LLC raised its position in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Gilead Sciences by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock valued at $650,009,000 after purchasing an additional 224,960 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last three months. Company insiders own 0.16% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.00 during mid-day trading on Friday, hitting $96.04. The company had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The stock's 50-day moving average price is $93.04 and its 200-day moving average price is $86.76. The company has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Robert W. Baird boosted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Barclays increased their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 7th. Piper Sandler boosted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Finally, Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an "outperform" rating and a $110.00 price objective for the company. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.